Teva Pharmaceutical Industries Limited (NYSE:TEVA) tinted gains of +0.44% (+0.07 points) to US$16. The volume of 10.2 Million shares climbed down over an trading activity of 10.2 Million shares. EPS ratio determined by looking at last 12 month figures is -2.23. Over the same time span, the stock marked US$25.96 as its best level and the lowest price reached was US$14.59. The corporation has a market cap of US$18.1 Billion.
Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s earnings per share has been growing at a -28.5 percent rate over the past 5 year when average revenue increase was noted as -1.5 percent. The return on equity ratio or ROE stands at -16.6 percent while most common profitability ratio return on investment (ROI) was -3.2 percent. The company’s institutional ownership is monitored at 64.3 percent. The company’s net profit margin has achieved the current level of -12.7 percent and possesses 44 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 17 think it is Hold. Recently, analysts have updated the overall rating to 2.75. 2 analysts recommended Overweight these shares while 2 recommended Underweight, according to FactSet data.
Pretium Resources Inc. (NYSE:PVG) is worth US$1.6 Billion and has recently risen 2.47% to US$8.7. The latest exchange of 1.42 Million shares is below its average trading activity of 2.15 Million shares. The day began at US$8.5 but the price moved to US$8.49 at one point during the trading and finally capitulating to a session high of US$8.82. The stock tapped a 52-week high of US$9.84 while the mean 12-month price target for the shares is US$13.66.
Currently, the stock carries a price to earnings ratio of 43.5, a price to book ratio of 1.77, and a price to sales ratio of 3.51. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 71.43%, it carries an earnings per share ratio of 0.2.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.14.